Eutilex.Co.,Ltd

Equities

A263050

KR7263050007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
2,100 ^KRW	-2.55%		+7.03%	-37.87%

May. 16	Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Eutilex.Co.,Ltd. announced that it has received KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One

October 29, 2020

On October 30, 2020, Eutilex.Co.,Ltd. (KOSDAQ:A263050) closed the transaction.

Latest news about Eutilex.Co.,Ltd

Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Eutilex.Co.,Ltd(KOSDAQ:A263050) dropped from S&P Global BMI Index	23-09-18	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Eutilex.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding	21-05-19	CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding	21-05-11	CI
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA	21-01-26	CI
Eutilex.Co.,Ltd. announced that it has received KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One	20-10-29	CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One	20-10-21	CI
Eutilex Co.,Ltd. announced that it has received KRW 29 billion in funding	20-05-03	CI
Eutilex Co.,Ltd. announced that it expects to receive KRW 29 billion in funding	20-04-23	CI
CDMO business GenScript ProBio and Eutilex Co., Ltd. Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for Car-T Programs	20-04-07	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	19-06-24	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	19-06-24	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	19-06-24	CI
Eutilex Co.,Ltd. has completed an IPO in the amount of KRW 36.35 billion.	18-12-19	CI
Eutilex Co.,Ltd. has filed an IPO.	18-09-18	CI
Eutilex Co. Ltd Announces A Strategic Partnership with Zhejiang Huahai Pharmaceutical Ltd	17-11-06	CI
Zhejiang Huahai Pharma Enters into Licensing Agreement with Eutilex Co., Ltd	17-09-05	CI
Eutilex Co., Ltd. announced that it expects to receive CNY 196.64 million in funding from Zhejiang Huahai Pharmaceutical Co., Ltd.	17-08-31	CI
Eutilex Co., Ltd. announced that it has received KRW 21 billion in funding from DS Investment Management, Kolon Investment, Inc., G.N.TECH Venture Capital Co., Ltd., and other investors	16-12-07	CI
Eutilex Co. Ltd. Names Agustin de la Calle as Chief Business Officer	16-11-07	CI

Chart Eutilex.Co.,Ltd

Duration

Period

More charts

Company Profile

Eutilex Co., Ltd. is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
EUTILEX.CO.,LTD	-37.87%	56.34M
CSL LIMITED	+0.99%	91.72B
SAMSUNG BIOLOGICS CO.,LTD.	0.00%	39.44B
BIOGEN INC.	-10.35%	34.47B
UCB	+64.64%	26.7B
BIOMARIN PHARMACEUTICAL INC.	-16.15%	15.13B
INCYTE CORPORATION	-6.98%	13.27B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.77%	11.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.19%	10.54B
SWEDISH ORPHAN BIOVITRUM AB	+8.09%	9.41B

Biopharmaceuticals